Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

US FDA approves Novavax’s BLA for Covid-19 vaccine, Nuvaxovid: Gaithersburg, Maryland Tuesday, May 20, 2025, 14:00 Hrs [IST] Novavax, Inc. announced that the US Food and Drug Ad ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

The FDA also gave full approval to the Novavax COVID vaccine (Nuvaxovid) using this approach, approving it for those ages 65 ...

After delays, the FDA has greenlit the Novavax COVID vaccine for targeted groups. Learn more about the approval and what it ...

Plus: FDA approves COVID-19 vaccine developed in Gaithersburg; Robert Frost student to compete in National Spelling Bee ...

JN.1, a variant of Omicron BA.2.86, emerged in late 2023 with 30 immune-evasion mutations. It spreads more efficiently due to ...

U.S. stock futures were slightly lower on Tuesday after ending largely flat on Monday. Futures of major benchmark indices ...

Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval ...